Published in Curr Heart Fail Rep on June 24, 2017
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet (2014) 6.08
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation (2014) 1.77
Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol (2011) 1.69
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27
Lessons from the TOPCAT trial. N Engl J Med (2014) 1.26
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail (2010) 1.06
Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail (2012) 1.06
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol (2013) 1.03
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03
Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA (2013) 1.01
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J (2009) 0.98
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. Am Heart J (2010) 0.90
Re-visiting consent for clinical research on acute myocardial infarction and other emergent conditions. Prog Cardiovasc Dis (2012) 0.86
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J (2014) 0.84
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). Circulation (2017) 0.79
Site selection for heart failure clinical trials in the USA. Heart Fail Rev (2015) 0.78
Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Curr Heart Fail Rep (2017) 0.78
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep (2017) 0.78
Integrating electronic health records into the study of heart failure: promises and pitfalls. Eur J Heart Fail (2017) 0.75